The San Diego-based company, founded in 2018, aims to improve the efficacy, affordability, and reduce toxicity of cancer drugs. Trio Pharmaceuticals' experienced team has invented and developed approved cancer treatments, and their approach is distinct from the current standard of care. Unlike current single-agent drugs that inhibit either cancer cell growth or immunosuppression, Trio Pharmaceuticals' single-agent dual-action treatments will inhibit both. This approach will be effective for cancer patients who have failed immune checkpoint treatments due to resistance or low expression of PD1, PDL1, CTLA4, and other immune checkpoint pathways.